Patients are encouraged to maintain open communication with their GP, bariatric nurse, and dietitian, and to attend follow-up appointments consistently
Information presented on this website is not a substitute for, or alternative to, information from a qualified health care practitioner
While we strive to keep our content current with the latest research and clinical guidelines, it is intended for general informational purposes only
In the SURMOUNT-1 trial, tirzepatide produced average weight loss of 15-22.5% of body weight over 72 weeks depending on dose
How NAD Supports Energy Levels NAD injections offer a comprehensive energy boost by working at the cellular level
These characteristics fundamentally distinguish the peptide fragment from full-length human growth hormone therapy